Clinical Trial Update: Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study

View source ↗

Summary

This completed prospective multicenter Swiss registry study assesses the performance of 177Lu-PSMA-I&T radioligand therapy for metastatic castration-resistant p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-I&T (177Lu-PSMA-I&T)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: mCRPC | Status: COMPLETED